Recruiting

Sodium Chloride

Sponsor:

UCLA

Code:

NCT07487831

Conditions

Atopic Dermatitis (Eczema)

Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Sodium chloride tablets

Placebo Tablets

Study Details

Brief summary:

The goal of this clinical trial is to demonstrate the feasibility of a trial that examines the impact of changes in dietary sodium intake on skin sodium levels, atopic dermatitis, and psoriasis. In addition, it aims to generate preliminary data to begin to answer the following questions:

1. Is there an association between skin sodium concentration and atopic dermatitis and psoriasis severity?
2. Are changes in dietary sodium are associated with changes in skin sodium concentration and atopic dermatitis and psoriasis severity?

Researchers will compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake.

Participants will:

  • Follow a low-salt diet for the duration of the 13-week study
  • Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa
  • Visit the clinic up to 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

Conditions

Atopic Dermatitis (Eczema)

Psoriasis

Study ID

NCT07487831

Start date

Jul 14, 2026

Status verified date

Sep, 2026

Completion date

Mar 17, 2028

Anticipated

Primary completion date

Mar 17, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participants ages 18 years
  • Willing and able to undergo non-contrast MRI.

Exclusion Criteria:

  • Contraindications to MRI (such as cardiac pacemakers, claustrophobia, non-compatible intracranial vascular clips, IUDs, or other implants)
  • A cardiac event in the past 6 months
  • Impaired function of the liver or kidney (glomerular filtration rate <60 mL/min)
  • Medications that influence sodium excretion (e.g., diuretics or SGLT2 inhibitors)
  • Antibiotic or immunomodulatory medications within the last month
  • Contraindications to sodium tablets

(Topical medications used exclusively on the head/neck or hands/feet (e.g., antifungal nail treatment, antidandruff shampoo, acne cleansers) are acceptable. Topical and systemic eczema treatments are acceptable if the participant has been on a stable dose for at least 2 months and still meets the severity entry criteria. Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the disease severity inclusion criteria.)

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Sodium tablets first

Participants will be randomized to receive sodium tablets for weeks 2-6, no tablets for a washout period during weeks 7-8, then placebo tablets for weeks 9-13.

experimental: Placebo tablets first

Participants will be randomized to receive placebo tablets for weeks 2-6, no tablets for a washout period during weeks 7-8, then sodium tablets for weeks 9-13.

Interventions

Sodium chloride tablets

During the 5-week long sodium tablet intervention period, participants will receive five 1 g sodium chloride tablets each morning and four 1 g sodium chloride tablets each evening. Each sodium chloride tablet will contain 0.394 g or 17 mmol of sodium

Placebo Tablets

During the 5-week long placebo period, participants will receive five placebo tablets each morning and four placebo tablets each evening.

Primary outcome measure

  • Fidelity of low-salt diet [ Time Frame: 4 months ]
  • Feasibility measured by recruitment rates and exclusion and non-participation reasons [ Time Frame: 4 months ]
  • Retention rates [ Time Frame: 4 months ]

Central Contacts and Locations

Central contacts

Alicia Hamblin

925-549-7889Alicia.Hamblin@ucsf.edu

Katrina Abuabara, MD

415-514-9769katrina.abuabara@ucsf.edu

Locations

UCSF Mt Zion Campus

Recruiting

San Francisco, California, United States, 94115

Contacts

Alicia Hamblin

925-549-7889Alicia.Hamblin@ucsf.edu

Katrina Abuabara, MD

katrina.abuabara@ucsf.edu

Principal Investigator:

Katrina Abuabara, MD

San Francisco VA Medical Center

Recruiting

San Francisco, California, United States, 94121

Contacts

Alicia Hamblin

925-549-7889Alicia.Hamblin@ucsf.edu

Katrina Abuabara, MD

415-514-9769katrina.abuabara@ucsf.edu

Principal Investigator:

Katrina Abuabara, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Sep 9, 2026

Last verified

Sep, 2026

Keywords

  • sodium
  • salt
  • diet

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-09-09.